Consolidated Portfolio Review Corp’s State Street Health Care Select Sector SPDR ETF XLV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-7,095
Closed -$987K 442
2025
Q3
$987K Sell
7,095
-2,569
-27% -$348K 0.12% 182
2025
Q2
$1.3M Buy
9,664
+143
+2% +$19.3K 0.18% 130
2025
Q1
$1.39M Buy
9,521
+487
+5% +$70.7K 0.22% 108
2024
Q4
$1.24M Sell
9,034
-247
-3% -$36.1K 0.2% 121
2024
Q3
$1.43M Sell
9,281
-311
-3% -$47.1K 0.32% 74
2024
Q2
$1.4M Buy
9,592
+2,030
+27% +$291K 0.33% 79
2024
Q1
$1.12M Sell
7,562
-781
-9% -$112K 0.29% 90
2023
Q4
$1.14M Sell
8,343
-1,287
-13% -$167K 0.26% 104
2023
Q3
$1.24M Buy
9,630
+1,279
+15% +$170K 0.3% 90
2023
Q2
$1.11M Buy
8,351
+1,997
+31% +$263K 0.26% 97
2023
Q1
$823K Buy
+6,354
New +$830K 0.22% 113

Other funds holding XLV

Consolidated Portfolio Review Corp's XLV Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of State Street Health Care Select Sector SPDR ETF (XLV) in Q4 2025, closing a stake of 7,095 shares — an estimated $987K sold.

Consolidated Portfolio Review Corp first reported a position in XLV in Q1 2023 and held it in 11 quarters. The position peaked at $1.43M in Q3 2024. 1,833 funds tracked by Wall St. Rank hold XLV as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining State Street Health Care Select Sector SPDR ETF position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 7,095 State Street Health Care Select Sector SPDR ETF shares in Q4 2025, an estimated $987K.
  • Consolidated Portfolio Review Corp first reported a position in State Street Health Care Select Sector SPDR ETF in Q1 2023 and held it in 11 quarters.
  • Consolidated Portfolio Review Corp's State Street Health Care Select Sector SPDR ETF position peaked at $1.43M in Q3 2024.
  • 1,833 funds tracked by Wall St. Rank held State Street Health Care Select Sector SPDR ETF as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.